In RET-fusion positive NSCLC, the RET-selective TKIs selpercatinib and pralsetinib earned approval in 2021, as strong clinical activity was observed in the phase I/II LIBRETTO-001 and ARROW studies, both in treatment-naïve (ORR 84% and 72%, respectively) and previously treated patients (ORR 61% and 59%, respectively) [52,53]. The gene discussed is RET; the disease is non-small cell lung carcinoma.